Dasatinib, a tyrosine kinase inhibitor developed by Bristol Myers Squibb, has faced patent challenges and expirations.
When Does the Dasatinib Patent Expire?
The primary U.S. patent for dasatinib, also known by its brand name Sprycel, was U.S. Patent No. 7,585,858, which was issued on September 8, 2009, and expired on September 8, 2025 [1]. However, other patents related to the drug and its uses also exist, impacting its market exclusivity. Patent information can be complex, with multiple patents covering different aspects of a drug. For detailed patent timelines and specific expiration dates, resources like DrugPatentWatch.com can provide comprehensive data [2].
Why Are Companies Challenging Dasatinib Patents?
Companies aiming to produce generic versions of dasatinib often challenge existing patents. These challenges typically involve arguing that the patents are invalid, unenforceable, or that their proposed generic product does not infringe on the patent claims. Such legal battles are common in the pharmaceutical industry as generic manufacturers seek to enter the market once patent protection wanes or is overcome.
What Does Patent Exclusivity Mean for Sprycel?
Patent exclusivity grants the innovator company, Bristol Myers Squibb in this case, the sole right to market and sell dasatinib for a defined period. Once these patents expire, other pharmaceutical companies can seek regulatory approval to market generic versions of the drug, often leading to lower prices for consumers and healthcare systems.
How Do Biosimilars Relate to Dasatinib?
Dasatinib is a small molecule drug, not a biologic. Therefore, biosimilars, which are highly similar versions of complex biologic medicines, are not applicable to dasatinib. Instead, the development of generic versions by other manufacturers is the relevant pathway for market competition after patent expiry [3].